10 results about "Blood count" patented technology

The utility model discloses a portable peripheral blood cell counter which comprises a glass slide and a cover glass, and the cover glass is positioned at the upper end of the glass slide; the carrying and placing frame is arranged at the lower end of the glass slide, a rectangular placing open groove is formed in the upper end face of the carrying and placing frame, L-shaped positioning pieces are fixed to the four corners of the upper end of the rectangular placing open groove in the carrying and placing frame, and the glass slide is located in the rectangular placing open groove and clamped among the four L-shaped positioning pieces; the semicircular through groove is formed in the middle of the front end face and the rear end face of the carrying and placing frame, and the semicircular through groove vertically penetrates through the carrying and placing frame. According to the blood cell counter, external protection of glass slides and cover glass is achieved, the effect that each group of cover glass and glass slides are separated is achieved, and therefore the problems that a main body of an existing blood cell counter used for counting is made of glass slides and cover glass, the glass slides and the cover glass are prone to colliding with each other during placement, damage can occur, and peripheral blood cell counting is affected are effectively solved.

To provide a skin condition estimation method.SOLUTION: A skin condition estimation method comprises: a step for acquiring psychosomatic data related to the body and mind of a subject of skin condition estimation; and a step for estimating the subject's skin condition using a skin model in which the correlation between the psychosomatic data and skin conditions is described. The psychosomatic data includes at least one of a liver function-related variable, a muscle / skeleton-related variable, a heart rate / blood pressure-related variable, a blood oxidation-related variable, a blood count-related variable, a lipid metabolism-related variable, an autonomic function-related variable, a personal attribute-related variable, a renal function-related variable, a body composition-related variable, a glucose tolerance-related variable, an electrolyte-related variable, a cognitive function-related variable, an immunometabolism-related variable, and a depression / fatigue / drowsiness-related variable.SELECTED DRAWING: Figure 3

The invention relates to the technical field of fermentation production and product quality control, in particular to a rapid counting method for bradyrhizobium. The rapid counting method specifically comprises the following steps: diluting bradyrhizobium, mixing the diluted bradyrhizobium with methylene blue dye liquor for dyeing, and then performing pulsed electric field assisted dyeing, and counting by using a blood cell counting plate to obtain the effective viable count of the bradyrhizobium. The methylene blue dye liquor specifically comprises a methylene blue aqueous solution and a phosphate buffer which are mixed according to the volume ratio of 1: 1; the methylene blue aqueous solution comprises the following components by concentration: 0.1-0.3% of methylene blue; 0.3 to 1.7 percent of beta-cyclodextrin; 3 to 5% of PEG-4000 (polyethylene glycol 4000); 0.01% to 0.05% of Triton X-100; and 0.02 to 0.2 percent of carboxymethyl chitosan. According to the rapid counting method provided by the invention, the effective viable count can be obtained within 2 hours, and the result accuracy is relatively high.

A kit, method, and software for quantifying red blood cells (erythrocytes), white blood cells (leucocytes), and platelet cells (thrombocytes) in a whole blood sample. The method comprises inter alia a contacting of solubilized proteins of the whole blood sample with labeled receptors binding to hemoglobin, CD42b antigen, and CD45 antigen and performing of immunochromatographic tests for hahemoglobinCD42b and CD45. The amounts of target analytes are quantitated and levels of CD45, CD42b, and hemoglobin are correlated with expected values and ranges found in healthy individuals and / or previously measured in the blood of an individual with a diagnosed neoplasia. The quantitation is done using a smartphone app for telemedicine. The method improves the Quality of Life of patients by considerably reducing waiting and travel times in the medical facility and by an improved on of therapy.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

The embodiment of the invention provides a construction method of a thalassemia screening model, equipment, a medium and a program product, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring a whole blood cell counting parameter and a classification label of a training set sample; the training set samples are divided into minority class samples and majority class samples according to the types of the classification labels; calculating k neighbors of each minority class sample, and dividing the minority class samples into dangerous samples and non-dangerous samples according to the proportion of majority class samples in the neighbors; selecting any sample from m nearest minority-class neighbors of each dangerous sample as a neighbor sample to be tested, and generating a new sample on a connecting line of the single dangerous sample and the neighbor sample to be tested through linear interpolation; and training the parameters of the new samples, the majority samples and the non-dangerous samples to obtain a screening model. According to the application, a robust multi-class screening model is established by using conventional whole blood cell count data so as to accurately distinguish key thalassemia genotypes.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

A PRP analyzing system is constructed and programmed to determine a baseline complete blood count of a whole blood sample and a blood count of PRP derived from the sample. The system compares the baseline and PRP blood counts and calculates qualitative PRP metrics such as constituent percentage yield, concentration and deliverable of PRP constituents. This provides immediate, understandable and compelling indication of the likely performance and effectiveness of the PRP in medical applications.

The present invention relates to pharmaceutical products comprising fluticasone furoate for use in the treatment of COPD patients, particularly a subgroup of COPD patients that through analysis have been identified as possessing an eosinophil blood count of ≥150 cells / μl. The present invention is further directed to methods for treating a patient with COPD which methods include identifying a patient that will respond to treatment and administering a pharmaceutical product of the present invention comprising fluticasone furoate to said patient.

The embodiment of the invention discloses a valuing method for simulating cell viability measurement by adopting a fluorescent label counting standard substance, and relates to the technical field of biological detection. The method comprises the following steps: preparing a fluorescent microsphere suspension; pretreating the suspension liquid; dropwise adding the suspension into a counting chamber of a blood counting plate; respectively counting in a bright field environment and a dark field environment of the microscope; calculating the luminous efficiency of the microspheres and the cell viability according to the counting result of the microscope; measuring for multiple times, and taking an average value as a constant value result; analyzing and calculating the uncertainty of the standard substance; and verifying the constant value method. The valuing method provided by the invention has good accuracy, reliability and quantity traceability, and further provides a reliable basis for quantitative analysis of the cell viability.